Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060356 · ClinicalTrials.gov registry record · Early Phase 1
Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 77
- Enrollment target
NCT03060356: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT03060356 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03060356, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains (referred to as "RNA CART-cMET") in patients with advanced melanoma or breast carcinoma.
Interventions
- BIOLOGICAL T cells modified with RNA anti -cMET CAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-12-21 |
| Est. Completion | 2020-03-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03060356
The ClinicalTrials.gov registry entry for NCT03060356 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which T cells modified with RNA anti -cMET CAR is the first listed.
NCT03060356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03060356 about?
NCT03060356 is a clinical study titled "Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)". This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains (referred to as "RNA CART-cMET")...
What is the current status of trial NCT03060356?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 77 participants. The study started on 2016-12-21. Estimated completion is 2020-03-27.
What interventions are being tested in trial NCT03060356?
The interventions under investigation include: T cells modified with RNA anti -cMET CAR (BIOLOGICAL).
Who is sponsoring clinical trial NCT03060356?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.